Combination of at least two antiviral agents of direct action and ribavirina but not interfered, for use in the treatment of hcv (Machine-translation by Google Translate, not legally binding)

摘要

Combination of at least two direct-acting antiviral agents and ribavirin but not interferon, for use in the treatment of hcv. The present invention features combinations of direct acting antiviral agents (aads) for use in therapies with ribavirin but without interferon in the treatment of hcv, for a short time, such as no more than 12 weeks. The at least two aads comprise at least one hcv protease inhibitor which is a therapeutic agent 1 or compound 1, known as (2r, 6s, 13as, 14ar, 16as, z) -N- (cyclopropylsulfonyl) -6- ( - methylpyrazine-2-carboxamido) -5,16-dioxo-2- (phenanthridin-6-yloxy) -1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13a, 14, 14a, 15, 16, 16a-hexadecahydrocyclopropa [e] pyrrolo [1,2-a] [1,4] diazacyclopentadecin-14a-carboxamide, and at least one inhibitor of ns5a which is a therapeutic agent 4 or compound 4, known as dimethyl ( 2s, 2's) -1.1 '- ((2s, 2's) -2.2'-4.4' - ((2s, 5s) -1- (4-tert-butylphenyl) pyrrolidin-2,5, diyl ) bis (4,1-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidin-2, 1-diyl) bis (3-methyl-1-oxobutane-2,1-diyl) dicarbamate. (Machine-translation by Google Translate, not legally binding)